Krilogy Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Krilogy Financial’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-200	Closed	-$2K	–	185
2018 Q3	$2K	Buy	+200	New	+$1.34K	﹤0.01%	707
2018 Q2	–	Sell	-200	Closed	-$1K	–	197
2018 Q1	$1K	Hold	200	–	–	﹤0.01%	723
2017 Q4	$1K	Hold	200	–	–	﹤0.01%	726
2017 Q3	$1K	Hold	200	–	–	﹤0.01%	763
2017 Q2	$1K	Hold	200	–	–	﹤0.01%	687
2017 Q1	$1K	Hold	200	–	–	﹤0.01%	671
2016 Q4	$1K	Hold	200	–	–	﹤0.01%	671
2016 Q3	$1K	Hold	200	–	–	﹤0.01%	693
2016 Q2	$1K	Hold	200	–	–	﹤0.01%	705
2016 Q1	$1K	Hold	200	–	–	﹤0.01%	634
2015 Q4	$2K	Hold	200	–	–	﹤0.01%	375
2015 Q3	$2K	Buy	+200	New	+$2.67K	﹤0.01%	542

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Krilogy Financial's BCRX Position: Q4 2018 in Review

Krilogy Financial sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2018, closing a stake of 200 shares — an estimated $2K sold.

Krilogy Financial first reported a position in BCRX in Q3 2015 and held it in 12 quarters. The position peaked at $2K in Q3 2018. 123 funds tracked by Wall St. Rank hold BCRX as of Q4 2018.

Krilogy Financial reported no remaining BioCryst Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Krilogy Financial sold 200 BioCryst Pharmaceuticals shares in Q4 2018, an estimated $2K.
Krilogy Financial first reported a position in BioCryst Pharmaceuticals in Q3 2015 and held it in 12 quarters.
Krilogy Financial's BioCryst Pharmaceuticals position peaked at $2K in Q3 2018.
123 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.